Almac Group Awarded US patent for Ground-breaking DDRD Assay

Press/Media: Research

Description

Almac Group’s announced it has been granted U.S. patent protection for its DNA Damage Response Deficiency (DDRD) assay. The patent numbers issued are 9,670,547 and 9,677,140, each titled Molecular Diagnostic Test for Cancer, and are effective until 2031.

Period30 May 2017

Media contributions

1

Media contributions

  • TitleAlmac Group Awarded US patent for Ground-breaking DDRD Assay
    Degree of recognitionInternational
    Media name/outletApplied Clinical Trials
    Media typePrint
    Country/TerritoryUnited Kingdom
    Date30/05/2017
    DescriptionAlmac Group’s announced it has been granted U.S. patent protection for its DNA Damage Response Deficiency (DDRD) assay. The patent numbers issued are 9,670,547 and 9,677,140, each titled Molecular Diagnostic Test for Cancer, and are effective until 2031
    URLwww.appliedclinicaltrialsonline.com/latest-business-and-people-news-11
    PersonsPaul Harkin